Navigation Links
TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
Date:3/18/2008

LA JOLLA, Calif., March 18 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced it has initiated a Phase II study of NGX267, a muscarinic agonist in development for xerostomia, or dry mouth, secondary to Sjogren's syndrome.

The company is conducting a randomized, double-blind, placebo-controlled, cross-over study with a Latin square design to evaluate the safety, tolerability and efficacy of this once-a-day compound. Approximately 24 patients will be enrolled at three sites in the United States. In four distinct treatment periods, each patient will be randomized to receive a single dose of 10 mg, 15 mg and 20 mg of NGX267 and placebo. The order of treatment is determined by the Latin square design. The primary endpoint of the study is quantitative measure of salivary flow.

"As we previously announced, we are focusing our clinical development activities on maximizing the value of our lead compounds to take advantage of their versatility," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics. "Three Phase I studies have already demonstrated the safety and tolerability of NGX267. More importantly for patients suffering from xerostomia, two of these studies demonstrated statistically significant increases in salivary flow. We are well-positioned to advance NGX267 as a potential new treatment for xerostomia associated with Sjogren's syndrome."

In a Phase I multiple-dose study completed in September 2007, salivary flow increased linearly with doses of NGX267, and these increases were maintained over four days of dosing.

"Xerostomia is a hallmark symptom of Sjogren's syndrome, one of the most prevalent autoimmune disorders, striking as many as 4 million Amer
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
2. TorreyPines Therapeutics Reports Third Quarter 2007 Results
3. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
6. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
7. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
8. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
9. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
10. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
11. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2014)... 2014 NSG Precision Cells has ... and spectrophotometer calibration standards for over ... released many products that have transformed the spectroscopy ... their solid-state calibration standards. , NSG’s solid-state calibration ... release in 2008. NSG started manufacturing UV ...
(Date:7/18/2014)... N.Y. , July 18, 2014 Regeneron ... its second quarter 2014 financial and operating results on ... open.  The Company will host a conference call and ... Conference Call InformationTo access this call, ... link to the webcast may be accessed from the ...
(Date:7/18/2014)... at Urbana-Champaign have demonstrated that an array of ... like traditional photographic film to record light for ... of light (for example, distances less than ~600 ... acts as a "nanocamera" whereas the pBNAs are ... the effect (writing and curing) is seen in ...
(Date:7/18/2014)... Reflecting the importance of the evolution of Houston’s real ... the founder and president of Customized Real Estate Services ... new approach to the firm’s branding. , According to ... success of his or her commercial clients have grown exponentially ... first in this market to fully embrace the potential for ...
Breaking Biology Technology:How NSG Precision Cells Spectrophotometer Calibration Standards Makes NIR Work Easier 2How NSG Precision Cells Spectrophotometer Calibration Standards Makes NIR Work Easier 3'Nanocamera' takes pictures at distances smaller than light's own wavelength 2LEED AP Certified ITRA Global / Customized Real Estate Services Introduces New Approach to Its Branding 2
... Mass., Jan. 13 Alseres Pharmaceuticals, Inc. (Nasdaq: ... entered into a securities purchase agreement (the "Agreement") with Robert ... stock of the Company at a purchase price of $1.00 ... of $1 million. In connection with the Agreement, Mr. ...
... Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... been granted its 31st U.S. Patent, # 7,476,382, ... patent includes claims to pharmaceutical compositions containing reovirus. ... proprietary position for REOLYSIN(R)," said Mary Ann Dillahunty, ...
... (TSX: GEN), a company focused on developing blood-based ... and personalized health management, today announced it has ... for the detection of Chagas disease related gene ... discovery of a blood biomarker-based method of testing ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 2Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 3Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 4Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent 2GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform 2
(Date:7/21/2014)... every movement, researchers have shown for the first time ... farms and pipelines. Those man-made structures probably serve as ... study published in the Cell Press journal Current ... shocked when I first saw the stunning grid pattern ... wind farm in the United Kingdom, says Deborah Russell ...
(Date:7/21/2014)... California, San Diego School of Medicine-led study suggests that ... potentially serious health consequences of childhood weight gain or ... child reach a healthy weight. , The study is ... of Nutrition and Dietetics . , "Parents have a ... behaviors," said lead author Kyung Rhee, MD, and an ...
(Date:7/21/2014)... Lgar,s team at the INRS nergie Matriaux Tlcommunications ... a spatial and temporal resolution greatly exceeding that ... a femtosecond laser source to shoot a molecular ... vinylidene. An article presenting the advancement was recently ... . , "The approach we developed combines ...
Breaking Biology News(10 mins):Seals forage at offshore wind farms 2Parents rank their obese children as 'very healthy' 2
... in Washington, D.C., has been working toward tracking how ... C. , Dr. Maria Sjogren, a retired Army colonel ... treating liver disease, has enrolled 90 active-duty servicemembers in ... The virus, which affects the U.S. military at similar ...
... scientist Associate Professor Barbara Fazekas de St. Groth, a ... the firsttime the important role of T cells in ... a study involving 38 patients with Crohn's disease and ... disease (IBD), and 43 healthy controls, Assoc Prof Fazekas ...
... commercially available gene chips to scrutinize all of ... cause genetic diseases. Because currently used genetic tests ... may lead to more accurate diagnosis of congenital ... retardation. , "For years, many children who have ...
Cached Biology News:Researcher studies, treats military with 'silent disease' 2Researcher studies, treats military with 'silent disease' 3Researcher studies, treats military with 'silent disease' 4Prevention is the best option: fighting autoimmune diseases 2Speeding the search for elusive chromosomal errors 2Speeding the search for elusive chromosomal errors 3Speeding the search for elusive chromosomal errors 4
Request Info...
... Printing Kit contains choice of Printing Surface (3 glass ... Ti adhesion layer, 1 silicon wafer coated with 1000 ... plain glass slides), PDMS Stamps (3 PDMS micropatterned stamps ... 100 um x 10 mm or 200 um x ...
Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: New Recommended Storage: Long term: -20C; Short term: +4...
...
Biology Products: